Japan’s Daiichi Sankyo has joined an open innovation research initiative that will try to develop a therapy for type 1 diabetes based on insulin-producing cells. The drugmaker has teamed up with ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

Daiichi Sankyo has succeeded in a bid to convince the US Patent and Trademark Office (PTO) to take another look at a patent held by Seagen that was previously deemed to have been infringed by its ...

Daiichi Sankyo will seek to maintain its edge over competitors in precision cancer therapies by pushing ahead with clinical trials of drug candidates being developed using new technology ...

Japan's Daiichi Sankyo applies for approval of mRNA COVID vaccine Approval would give Japan a home-grown mRNA vaccine of the type that has made up the bulk of its COVID inoculations so far.

As one of the leading Japanese pharmaceutical companies with headquarters in Europe, Daiichi Sankyo aims to revolutionize treatment standards. Daiichi Sankyo, a pharmaceutical group boasting over ...

Hiroyuki Okuzawa, President and COO at Daiichi Sankyo, says the company is working to boost production of its newer-generation cancer therapies that target diseased cells, across Japan ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Kartik Purnima (Hindi: कार्तिक पूर्णिमा, Gujarati: કારતક સુદ પૂર્ણિમા, Tamil ...

Kartik Aaryan was born in Gwalior, Madhya Pradesh. He pursued a degree in engineering before making a career in acting. He made his acting debut in 2011 with Luv Ranjan's film Pyaar Ka Punchnama.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...